The peroxisome proliferator-activated receptor-b/d (PPARb/d) 
Introduction
Mast cells derived from bone marrow progenitors are found in many types of tissues where their differentiation is influenced by the tissue microenvironment. 1, 2 In addition to expression of the high-affinity receptor for IgE (FceRI), mature mast cells contain a large amount of secretory granules filled with preformed and actively synthesized molecules, including amines, proteases, enzymes, peptides and cytokines. 3 These mast cell molecules can be released into the extracellular environment following mast cell activation and/or degranulation and mediate different biological effects. 3 Hence, mast cells not only contribute to allergic inflammation through the antigen-dependent secretion of histamine and inflammatory factors, but also have an important role in regulating infectious agentmediated innate immunity. 4 Peroxisome proliferator activated receptor-b/d (PPARb/d) regulates diverse cellular activities, including cell proliferation, differentiation, inflammation, and lipid and glucose homeostasis. 5, 6 Although PPARb/d is expressed in both human and mouse mast cells, 7, 8 the intrinsic role of PPARb/d in the function of mast cells has yet to be extensively evaluated. There is a large body of evidence indicating that PPARb/d promotes anti-inflammatory activities in many cell types. 9 For example, it was shown that PPARb/d protects against experimentally induced colitis. 10 Additionally, PPARb/d attenuates immune cell infiltration in the dermis and subcutaneous tissue in response to topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA). 11 TPA is known to induce mast cell activation, 12 which is important for the recruitment of other immune cell types, such as neutrophils, T cells and monocytes. 3 Collectively, these observations
Transmission electron microscope and qualitative assessment of BMMC maturation
After culturing with IL-3 and IL-3/SCF for 6-8 weeks, BMMCs derived from Pparb/d +/+ and Pparb/d À/À mice were fixed in 2% glutaraldehyde in 0Á1 M sodium cacodylate buffer (pH 7Á4), post-fixed in 1% osmium tetroxide, dehydrated with serial ethanol dilutions and embedded in Eponate. Ultrathin sections (80 nm) were stained with uranyl acetate and lead citrate, and analysed with a transmission electron microscope (JEOL JEM 1200 EXII, Peabody, MA). Stages of mast cell maturation were determined by the granule number and structure as previously described. 16 Resting mast cells were then classified into five groups, indicating their maturity: stage A, fully mature BMMCs filled with dense granules and no empty chamber; stage B, mature BMMCs with a few empty chambers and a few chambers filled with dense granules; stage C, incompletely mature BMMCs containing a large number of chambers with dense but small granules; stage D, immature BMMCs containing large chambers with diffuse granules; stage E, immature BMMCs with large empty chambers. To induce degranulation, BMMCs were also sensitized with 1 lg/ml mouse anti-dinitrophenyl-IgE (clone SPE-7; Sigma-Aldrich) and then activated by 100 ng/ml dinitrophenyl-human serum albumin (DNP-HSA) (Sigma-Aldrich) for 4 hr. Five mice per genotype and 30-40 mast cells per mouse were assessed.
Cell proliferation assay
Cell proliferation was determined by flow cytometry using a carboxyfluorescein succinimidyl ester (CFSE) proliferation kit (Life Technologies, Carlsbad, CA) following the manufacturer's recommended procedure. BMMCs (2 9 10 6 ) derived from Pparb/d +/+ and Pparb/d À/À mice were initially labelled with 5 lM CFSE, and cell proliferation was monitored by flow cytometry up to 5 days. Cells treated with 10 lg/ml mitomycin C (Sigma-Aldrich) to induce cell cycle arrest were used as a control.
Cell survival and apoptosis
Growth factor withdrawal has been shown to induce apoptosis in many types of cells, including mast cells. mice were pre-treated with or without GW0742 (1 lM), a specific PPARb/d agonist, for 1 hr and then incubated in media without IL-3 and SCF in the presence or absence of GW0742 for up to 6 days. Cell numbers were counted daily with a Coulter counter and survival rates in response to IL-3 and SCF withdrawal were determined. At the end of the experiment, cells were stained with 7-aminoactinomycin D and annexin V-FITC (eBioscience) following the manufacturer's recommended procedures. Apoptosis was measured with a Cytomic FC500 flow cytometer (Beckman Coulter).
Antigen-dependent and antigen-independent activation of BMMCs
To induce antigen-mediated activation, BMMCs (2 9 10 6 ) were sensitized overnight with 1 lg/ml mouse anti-DNP-IgE (IgE) and then activated by 100 ng/ml DNP-HSA for 4 hr. To induce an antigen-independent response, BMMCs (2 9 10 6 ) were treated with 100 ng/ml lipopolysaccharide (LPS) or 500 nM TPA for 24 hr. Both LPS and TPA were purchased from Sigma-Aldrich. BMMCs (2 9 10 6 ) were also exposed to UVB (280-315 nm, 50 mJ/cm 2 ) using a CL-1000 Ultraviolet Crosslinker (Ultra-Violet Products, Upland, CA) and then cultured for 24 hr post-UVB exposure.
Preparation of peritoneal mast cells
Peritoneal cells were collected from Pparb/d +/+ and Pparb/d À/À mice as previously described. 18 Peritoneal cells (2 9 10 4 ) were cytospun onto glass slides and stained with toluidine blue. Peritoneal mast cells (PMCs) (c-KIT + /FceRI + ) were identified by Cytomic FC500 flow cytometer (Beckman Coulter) using anti-CD117 (c-KIT)-FITC and anti-FceRIa-PE antibodies (eBioscience, San Diego, CA), and the number of PMCs was then quantified. The total number of peritoneal cells was normalized by body weight, and the percentage of PMCs was calculated by dividing the number of PMCs with total number of peritoneal cells.
To induce cytokine production, PMCs were cultured in medium containing LPS (100 ng/ml) or TPA (500 nM) followed by the addition of a protein transport inhibitor, brefeldin A (eBioscience, San Diego, CA). PMCs were then fixed and stained with anti-IL-10-APC antibody (eBioscience, San Diego, CA) following the manufacturer's recommended protocol. Intracellular expression of IL-10 in c-KIT + /FceRI + PMC populations was determined with a Cytomic FC500 flow cytometer.
Western blot analysis
Quantitative Western blot analysis using a radioactive detection method was performed as previously described. 19 To analyse the expression of phosphoproteins, BMMCs (2 9 10 6 ) were homogenized in RIPA buffer supplemented with a protease inhibitor cocktail, 5Á4 mM sodium pyrophosphate, 50 mM sodium fluoride and 1 mM sodium orthovanadate (Sigma-Aldrich). Membranes were blocked with either 5% non-fat milk or phosphoprotein blocker (Millipore, Billerica, MA). Primary antibodies included carboxypeptidase 3 (CPA3; ABBIOTEC, LLC, San Diego, CA), IjB, phospho-IjB, ACTIN (Santa Cruz Biotechnology, Santa Cruz, CA), phospholipase Cc1 (PLCc1), phosho-PLCc1, PLCc2, phosho-PLCc2, p65, phospho-p65, AKT, phospho-AKT, extracellular signal-regulated kinases (ERK), phospho-ERK, Jun N-terminal kinase (JNK), phospho-JNK (Cell Signaling Technology, Danvers, MA) and lactate dehydrogenase (Rockland Immunochemicals, Inc., Limerick, PA). The expression level of each protein was normalized to ACTIN or lactate dehydrogenase, and the normalized expression of the phosphoproteins was normalized to the non-phosphorylated protein of interest.
Quantitative real-time PCR
Expression of mast cell mediator genes in BMMCs in response to DNP-HSA, UVB, LPS and TPA treatment was determined by quantitative PCR analysis as previously described. 19 Mast cell mediator genes included carboxypeptidase A3 (Cpa3), b-hexosaminidase A (Hexa), b-hexosaminidase B (Hexb), mast cell protease 4 (Mcpt4), chymase 1 (Cma1, also known as Mcpt5), tryptase b-2 (Tpsb2, also known as Mcpt6), Il6, Il10, tumour necrosis factor-a (Tnfa) and vascular endothelial growth factor (Vegf). Each assay included a standard curve and a non-template control that were performed in triplicate. Relative mRNA levels of target genes were normalized to the mRNA level of glyceraldehyde-3-phosphate dehydrogenase (Gapdh).
Cytokine assay
To determine secretory cytokine levels in mast cells, MILLIPLEX MAP Multiplex cytokine assays (EMD Millipore, Billerica, MA) were used following the manufacturer's recommended procedures. Basal levels of 17 mouse cytokines, including granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor, interferon-c, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, monocyte chemo-attractant protein-1, tumour necrosis factor-a (TNF-a), vascular endothelial growth factor and macrophage inflammatory protein-2, in supernatants of BMMCs (2 9 10 6 ) derived from Pparb/d +/+ and Pparb/d À/À mice were quantified 24 hr after culture using a Bio-Plex multiplex system (Bio-Rad, Hercules, CA).
Statistical analysis
The data were subjected to either Student's t-test or a parametric one-way analysis of variance followed by Tukey test for post hoc comparisons (PRISM 5.0, GraphPad Software Inc., La Jolla, CA). 2d) and may reflect the difference in degranulation observed in the resting phase between genotypes ( and Pparb/d À/À mice were cultured for 6 weeks in the presence of IL-3 and SCF, and then cultured in media without IL-3 and SCF for up to 6 days. Cytokine deprivation caused a gradual decrease in survival rates of BMMCs from both genotypes (Fig. 3c ). Ligand activation of PPARb/d with the specific agonist GW0742 had no effect on survival rates in either genotype in response to cytokine withdrawal (Fig. 3c) . No significant differences in apoptosis or late apoptosis/necrosis of BMMCs were observed between genotypes in response to cytokine depletion ( Fig. 3d ). and Pparb/d À/À mice (Fig. 4 g ). LPS treatment had no effect on IL-10 expression in either genotype (Fig. 4 g) (Fig. 5a ). The change in relative expression of CPA3 was confirmed at the protein level as well (data not shown). Moreover, compared with BMMCs from Pparb/d À/À mice, BMMCs from Pparb/d +/+ mice secreted lower levels of cytokines, including granulocyte-macrophage colony-stimulating factor, interferon-c, IL-2, IL-3, IL-4, IL-6, IL-10, TNF-a and macrophage inflammatory protein-2 (Fig. 5b) . Mast cell mediators released to the extracellular environment are controlled by a complicated kinase and enzyme network, 21, 22 (Fig. 5b) . To induce antigen-dependent activation, BMMCs were treated with IgE and DNP-HSA. Antigen stimulation had no effect on Il6, Il10 and Vegf mRNA expression in BMMCs from Pparb/d +/+ mice (Fig. 6a ), but caused increased Tnfa expression (Fig. 6a) . The lack of change in Il6 mRNA expression in Pparb/d +/+ BMMCs may reflect the timing of analysis as this was measured 4 hr post-activation, and peak Il6 mRNA expression occurs 1 hr post-activation. 23 By contrast, BMMCs from Pparb/d À/À mice exhibited higher basal levels of Il6, Il10, Tnfa and Vegf mRNA compared with Pparb/d +/+ BMMCs, but lower expression of Il6 and Il10 mRNA and a greater induction of Tnfa and Vegf expression in response to IgE and DNP-HSA treatment (Fig. 6a) . Secretion of IL-6 was increased in response to IgE and DNP-HSA in Pparb/d (Fig. 6b) . However, Il10 mRNA expression was significantly increased in BMMCs from Pparb/d +/+ mice compared with control (Fig. 6b) . In contrast, UVB irradiation decreased Il6, Tnfa and Vegf mRNA expression in BMMCs from Pparb/d À/À mice (Fig. 6b) , but showed no effect on Il10 mRNA expression (Fig. 6b) . Secretion of IL-6 was increased in response to UVB exposure in both Pparb/d +/+ and Pparb/d À/À BMMCs, and basal secretion 
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) (Fig. 6c) , However, LPSinduced cytokine production was only observed in Il10 and Vegf mRNA expression in BMMCs from Pparb/d À/À mice (Fig. 6c) . Similarly, TPA caused increased expression of Il6, Il10, Tnfa and Vegf mRNA in BMMCs from Pparb/d +/+ mice (Fig. 6d) . No significant difference was observed in Il6 and Il10 mRNA levels in in BMMCs from Pparb/d À/À mice following TPA treatment (Fig. 6d) .
TPA-treated BMMCs from Pparb/d À/À mice exhibited higher Tnfa and lower Vegf expression compared with controls (Fig. 6d) .
Discussion
As mice were observed. To date, whether PPARb/d is proapoptotic or anti-apoptotic remains controversial (reviewed in refs 5,6); however, results from the present study support previous work showing that PPARb/d has no direct effect on apoptosis. 19, 26 There are two primary subtypes of mast cells: connective tissue mast cells residing in the skin, peritoneal cavity and submucosa of the intestinal tract, and mucosal mast cells located at mucosal surfaces. 27 These two types of mast cells differ in their histochemical properties, mediator contents and the responses to mast cell activation. 27, 28 In the present study, BMMCs from Pparb/d 29 hence, the effects observed in the present studies may support this hypothesis.
The N-MYC downstream-regulated gene 1 (NDRG1) is a key regulator of maturation of connective tissue mast cells. 28 Similar to the present study, genetic disruption of the Ndrg1 gene in mice results in a reduction of basal and inducible degranulation capacity of mast cells associated with decreased PLCc1 activity.
14 Although the ability of PPARb/d to regulate degranulation requires further characterization, this is similar to the phenotype observed with BMMCS from Pparb/d À/À mice. Hence, based on The anti-inflammatory role of PPARb/d has also been examined in several models, including monocytes, macrophages, dendrite cells and endothelial cells, where it is also important for cell quiescence. 9 As noted above, earlier work suggested that ligand activation of PPARb/d inhibits cytokine production. 7 Numerous studies have established that PPARb/d down-regulates expression of pro-inflammatory mediators by interfering with the p65 subunit of the nuclear factor-jB complex. 9 Further experimentation is needed to determine whether this mediates the similar effects observed in BMMCs in the present study. There is also evidence that ligand activation can repress expression of IL-10. 34 Consistent with this observation, enhanced expression of IL-10 expression was noted in BMMCs from Pparb/d À/À mice. As IL-10 is known to have anti-inflammatory activities, further studies are needed to determine how PPARb/d modulates the balance of pro-inflammatory and anti-inflammatory cytokines and how this balance influences mast cell function. Mast cells are also capable of presenting antigens and effectively modulating innate immunity against pathogens, 35 which is known to be influenced by FceRI expression. 36 In the present study, BMMCs from Pparb/d sensitivity to chemically induced inflammation and were not capable of maintaining cytokine production in mast cells. It is well known that LPS induces cytokine production in mast cells without degranulation. 37, 38 The present study further demonstrated that the LPS-induced IL-6 and TNF-a expression are PPARb/d-dependent, whereas LPS-induced IL-10 and vascular endothelial growth factor expression are not. These observations support the view that PPARb/d is critical for modulating host defence against pathogens by modulating the inflammatory process. PPARb/d was reported to mediate FceRI expression associated with a decreased histamine release from human basophils. 39 However, neither FceRI nor c-KIT expression in mast cells was altered by the specific PPARb/d agonist GW0742 in the present study (data not shown). The different results between the previous study and the present study may be due to the fact that the relatively high concentration of PPARb/d ligands used in previous report may have caused off-target effects.
The mechanisms by which PPARb/d regulates inflammation involve complex networks of tissues and immunological components. The present study demonstrates PPARb/d-dependent effects in mast cell responses to various stimuli, establishing that PPARb/d may be important to orchestrate inflammatory responses in mast cells. How PPARb/d could be a viable cellular target for the therapeutic intervention of mast cell-mediated disorders remains to be further investigated.
